Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AUPH

Aurinia Pharmaceuticals Inc

May 07 • 04:00PM ET

15.14

-1.11 -6.80 %

Healthcare • Biotechnology • Canada • Mid • NASD

May 07, 10:19 AMAurinia Pharmaceuticals beats fiscal Q1 2026 EPS and revenue estimates with EPS $0.25, revenue $77.7M, and issues full-year revenue guidance of $315M-$325M

Peers: VERA TVTX IMVT KYTX NRIX

| Held by: IWM IWO IBB JSMD VTWO VHT FESM AVSC JSML SPDW

Scroll to Statements

Index	RUT	P/E	7.00	EPS (ttm)	2.16	Insider Own	11.45%	Shs Outstand	130.77M	Perf Week	-1.59%
Market Cap	2.01B	Forward P/E	13.58	EPS next Y	1.11	Insider Trans	6.28%	Shs Float	117.74M	Perf Month	-4.72%
Enterprise Value	1.70B	PEG	-	EPS next Q	0.23	Inst Own	57.96%	Short Float	7.74%	Perf Quarter	6.17%
Income	298.21M	P/S	6.75	EPS this Y	-55.88%	Inst Trans	5.92%	Short Ratio	8.32	Perf Half Y	6.10%
Sales	298.30M	P/B	3.49	EPS next Y	22.08%	ROA	48.54%	Short Interest	9.11M	Perf YTD	-5.08%
Book/sh	4.34	P/C	5.31	EPS next 5Y	-13.42%	ROE	64.98%	52W High	16.88 -10.31%	Perf Year	86.68%
Cash/sh	2.85	P/FCF	12.06	EPS past 3/5Y	- -	ROIC	48.24%	52W Low	7.28 107.82%	Perf 3Y	30.97%
Dividend Est.	-	EV/EBITDA	11.40	Sales past 3/5Y	28.30% 41.38%	Gross Margin	89.74%	Volatility	5.28% 3.65%	Perf 5Y	49.24%
Dividend TTM	-	EV/Sales	5.71	EPS Y/Y TTM	5205.15%	Oper. Margin	43.58%	ATR (14)	0.63	Perf 10Y	508.03%
Dividend Ex-Date	-	Quick Ratio	5.01	Sales Y/Y TTM	20.62%	Profit Margin	99.97%	RSI (14)	44.37	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.55	EPS Q/Q	53.13%	SMA20	-4.71%	Beta	1.45	Target Price	17.00
Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	24.40%	SMA50	-0.02%	Rel Volume	2.62	Prev Close	16.25
Employees	128	LT Debt/Eq	0.09	Earnings	May 07 BMO	SMA200	8.75%	Avg Volume	1.10M	Price	15.14
IPO	Oct 20, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	28.21% 0.94%	Trades		Volume	2,799,757	Change	-6.80%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$16
Nov-07-25	Upgrade	Jefferies	Hold → Buy	$21
Nov-05-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15
Jul-30-25	Resumed	H.C. Wainwright	Buy	$17
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11

Show Previous Ratings

May-07-26 08:06AM	Aurinia: Q1 Earnings Snapshot (Associated Press) -6.80%
Mar-30-26 11:00AM	United rises on IPF results; Biogen scores positive lupus data and an approval (BioPharma Dive)
11:00AM	United rises on IPF data; Biogen scores positive lupus data and an approval (BioPharma Dive)
Mar-23-26 12:13PM	Mutiny At Aurinia Pharmaceuticals? Biotech Soars On C-Suite Shake-Up. (Investor's Business Daily)
11:00AM	MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition (Business Wire)
08:00AM	Loading…
08:00AM	Aurinia Announces Management Transition (Business Wire)
Mar-13-26 08:29PM	W.R. Berkley, Ziff Davis, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-04-26 01:35PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily) +6.29%
Mar-01-26 04:27AM	Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 (Insider Monkey)
Feb-26-26 08:03PM	Aurinia Pharmaceuticals Inc. Q4 2025 Earnings Call Summary (Moby)
04:10PM	Aurinia Pharmaceuticals Inc (AUPH) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
04:06PM	Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets (Benzinga)
12:06PM	Aurinia Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:15AM	Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:12AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Loading…
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress (Business Wire)
Feb-25-26 12:15PM	United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates (Zacks)
Feb-24-26 01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
01:02PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Feb-19-26 06:00AM	Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 (Business Wire)
Feb-11-26 05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
Feb-06-26 02:03PM	This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base (Investor's Business Daily)
Jan-13-26 02:20PM	Moderna Stock Gets Healthy Relative Strength Rating Jump (Investor's Business Daily)
Dec-26-25 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-10-25 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
Dec-05-25 12:00PM	What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-02-25 10:15AM	Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options (Zacks)
Nov-27-25 09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-24-25 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-18-25 02:19PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
01:17PM	Loading…
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-07-25 12:20PM	Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates? (Zacks)
Nov-04-25 04:05PM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call Highlights: Strong Lupkynis Sales and ... (GuruFocus.com) +8.35%
07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
06:11AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress (Business Wire)
Nov-03-25 06:00AM	Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 (Business Wire)
05:00AM	Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark (BioPharma Dive)
04:49AM	Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir (The Wall Street Journal)
Nov-02-25 07:59PM	FDA Official Steps Down, Sued by Drugmaker (The Wall Street Journal)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-15-25 06:00AM	Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 (Business Wire)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-30-25 12:34PM	Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-29-25 08:27PM	Aurinia Responds to Now Retracted LinkedIn Post (Business Wire) -15.83%
03:19PM	Cytokinetics Stock Scores RS Rating Jump To 83 (Investor's Business Daily)
Sep-17-25 01:45PM	Oric Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-08-25 02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Sep-03-25 02:02PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily)
Aug-27-25 01:57PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-04-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know (Zacks) +9.15%
Aug-01-25 05:01AM	Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +13.47%
Jul-31-25 07:15AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates (Zacks)
06:13AM	Aurinia: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 (Business Wire)
Jul-22-25 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 (Business Wire)
Jul-02-25 08:48AM	Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options (Zacks)
Jun-30-25 06:00AM	Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) (Business Wire)
Jun-29-25 05:00PM	Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 (Business Wire)
Jun-27-25 08:56AM	Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
May-30-25 08:46AM	Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
May-22-25 06:00AM	New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis (Business Wire)
May-13-25 09:24AM	Company News for May 13, 2025 (Zacks)
03:03AM	Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-12-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
06:07AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 (Business Wire)
May-05-25 06:00AM	Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 (Business Wire)
Apr-30-25 06:00AM	Glass Lewis Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-29-25 06:00AM	ISS Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-26-25 10:54AM	Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (Seeking Alpha)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 04:05PM	Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting (Business Wire)
09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
Mar-25-25 10:41AM	Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-07-25 04:47PM	Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-04-25 01:14PM	Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
Feb-28-25 02:13AM	Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.30%
Feb-27-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates (Zacks) -5.03%
06:28AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress (Business Wire)
Feb-25-25 12:31PM	Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-20-25 04:05PM	Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 (Business Wire)
Jan-22-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's Why (Zacks)
Dec-10-24 08:30AM	Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options (Zacks) +14.35%
Nov-18-24 05:53PM	Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis (Business Wire)
Nov-15-24 06:00AM	Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024 (Business Wire)
Nov-14-24 06:00AM	Aurinia to Participate in Jefferies London Healthcare Conference (Business Wire)
Nov-08-24 10:30AM	Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets (Pharmaceutical Technology)
06:37AM	Aurinia Pharmaceuticals Reports Strong Q3 Growth and Restructuring (TipRanks)
02:12AM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-07-24 07:40AM	Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates (Zacks) +10.90%
06:41AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:10AM	Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth (Business Wire)
06:00AM	Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development (Business Wire)
Oct-30-24 04:05PM	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 (Business Wire)

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TANG KEVIN	Director	Feb 27 '26	Buy	13.99	516,439	7,226,535	11,845,939	Mar 03 05:35 PM
TANG KEVIN	Director	Mar 02 '26	Buy	14.26	199,353	2,842,833	12,045,292	Mar 03 05:35 PM
TANG KEVIN	Director	Mar 03 '26	Buy	14.22	184,208	2,619,438	12,229,500	Mar 03 05:35 PM
TANG KEVIN	Director	Aug 01 '25	Buy	10.12	1,000,000	10,120,000	11,029,500	Aug 05 05:31 PM
TANG KEVIN	Director	Aug 05 '25	Buy	11.68	200,000	2,336,000	11,329,500	Aug 05 05:31 PM
TANG KEVIN	Director	Aug 04 '25	Buy	11.34	100,000	1,134,000	11,129,500	Aug 05 05:31 PM
Keenan Greg	Chief Medical Officer	Aug 01 '25	Sale	10.50	20,000	210,000	133,484	Aug 05 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AUPH

Aurinia Pharmaceuticals Inc

Upgrade your Finviz experience